Researchers in the Gynecologic Oncology Program are exploring gynecologic cancers from a wide variety of scientific angles – from discoveries about the genes that cause tumors to develop and grow, to investigations of novel therapies including targeted drugs and immunotherapies, and studies of ways drugs can be combined to fight recurrent cancer.
Our team is working with basic scientists to look at new ways to fight gynecologic cancers through laboratory studies, creating laboratory models to study cancer resistance, and researching how to exploit DNA repair defects. Our team is focused on the development of new treatments for specific subtypes of gynecologic cancers, as well as methods for early detection of ovarian cancer.
Clinical Trials
We base our treatments on the latest scientific findings and offer our patients the opportunity to participate in clinical trials of promising new treatments. Our clinical trial program is one of the largest and most active in the country, with more than 20 open studies.
Featured Clinical Trials
Ovarian Cancer Clinical Trials
- Trial 18-227: Phase 1/2 study of REGN4018 (a MUC16×CD3 bispecific antibody) administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer or other recurrent MUC16+ cancers
Principal investigator: Joyce F. Liu, MD, MPH - Trial 21-739: Phase 2 trial of pembrolizumab and lenvatinib in patients with recurrent or persistent clear cell carcinoma of the ovary
Principal investigator: Elizabeth K. Lee, MD - Trial 22-522: Randomized phase 3, two-arm trial of paclitaxel/carboplatin/maintenance letrozole versus letrozole monotherapy in patients with stage ii-iv, primary low-grade serous carcinoma of the ovary or peritoneum
Principal investigator: Alexi A. Wright, MD, MPH - Trial 23-221: Phase 1b/2 basket study of ACR-368 as monotherapy and in combination with gemcitabine in adult subjects with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon OncoSignature® status
Principal investigator: Panagiotis (Panos) A. Konstantinopoulos, MD, PhD - Trial 23-579: Phase 1/2a multi-center, open-label, master protocol to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of AZD8205 in participants with advanced or metastatic solid malignancies (D6900C00001)
Principal investigator: Joyce F. Liu, MD, MPH - Trial 23-702: Phase 1b dose optimization study of sovilnesib (an oral KIF18A inhibitor) in subjects with advanced high grade serous ovarian cancer
Principal investigator: Joyce F. Liu, MD, MPH - Trial 23-689: Phase 2 basket study of disitamab vedotin in adult subjects with previously treated, locally-advanced unresectable or metastatic solid tumors that express HER2
Principal investigator: Joyce F. Liu, MD, MPH - Trial 19-059: EFFORT: EFFicacy Of ceralasertib (AZD6738) and adavosertib (AZD1775) in PARP ResisTance: Randomized 3-arm non-comparative phase 2 study of adavosertib alone, adavosertib plus olaparib, and ceralasertib plus olaparib in women with ovarian cancer who have progressed during PARP inhibition
Principal investigator: Joyce F. Liu, MD, MPH - Trial 21-580: Phase 1b study of ZN-c3 in combination with chemotherapy or bevacizumab in subjects with ovarian, peritoneal, or fallopian tube cancer
Principal investigator: Joyce F. Liu, MD, MPH - Trial 23-613: Phase 2 open-label, multicenter study to evaluate efficacy and safety of ZN-c3 in subjects with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer
Principal investigator: Joyce F. Liu, MD, MPH